Resultados de procura - Manuel Constenla

  • Mostrando 1 - 7 Resultados de 7
Limitar resultados
  1. 1
    Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study

    Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study por Matthias Schwenkglenks, Ruth Pettengell, Christian Jackisch, Robert Paridaens, Manuel Constenla, André Bosly, Thomas D. Szucs, Robert Leonard

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study

    Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study por Ruth Pettengell, André Bosly, Thomas D. Szucs, Christian Jackisch, Robert Leonard, Robert Paridaens, Manuel Constenla, Matthias Schwenkglenks

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study

    Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study por Ruth Pettengell, Matthias Schwenkglenks, Robert Leonard, André Bosly, Robert Paridaens, Manuel Constenla, Thomas D. Szucs, Christian Jackisch

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study

    Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study por Oh, Hae-Jin Suh, Menéndez, Ángeles Flórez, Santos, Víctor Sacristán, Martínez, Ángeles Rodríguez, Ribeiro, Francisca Fernández, Vilanova-Trillo, Lucía, Figueiras, Manuel Constenla, Ferreiros, Manuel Pereiro

    Publicado 2021
    Ligazón do recurso Ligazón do recurso Ligazón do recurso
    Text
    Engadir a favoritos
    Gardado en:
  5. 5
    Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group

    Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcino... por Jaffer A. Ajani, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, C. Boni, Adriano Rodrigues, M Fodor, Yee Chao, Э К Возный, Lucile Awad, Eric Van Cutsem

    Publicado 2007
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

    Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study... por Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, C. Boni, Adriano Rodrigues, M Fodor, Yee Chao, Э К Возный, Marie-Laure Risse, Jaffer A. Ajani

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

    Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung ca... por Rafael Rosell, G. Robinet, A. Szczęsna, Rodryg Ramlau, Manuel Constenla, B. Mennecier, Wolfgang Pfeifer, Kenneth J. O’Byrne, Tobias Welte, Rainer Kolb, Robert Pirker, A. Chemaissani, M. Pérol, Malcolm Ranson, Peter Ellis, Korinna Pilz, M. Reck

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: